President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi. In the latest development, the European Commission has ...

It has previously signed a bi-specific immune-oncology antibody deal with China’s EpimAb and had begun early research with The Scripps Research Institute in California about a potential new ...

Several key factors fuel the need for new, high-tech production facilities. Rising investment in research and development within biotech has intensified demand for specialised production ...

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with ...

Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

"We are immensely thankful for the dedication to innovative research that has led to this approval, and we are ready to help families embark on this new chapter of treatment." In a statement ...

People with a form of severe epilepsy will now be able to get NHS access to a new drug from UCB, Fintepla, that could significantly reduce their seizures. The NHS will fund Fintepla (fenfluramine ...

With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first approved ...